Panacea Biotec PANACEABIO
Listed vaccine maker - WHO-prequalified pentavalent (Easyfive-TT) for UNICEF/Gavi, and a dengue vaccine (DengiAll) in Phase 3 with ICMR
Mapped in 1 theme: Pharmaceuticals.
Where Panacea Biotec sits in the supply chain
Panacea Biotec appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › Biosimilars, vaccines & biologics
Direct supplierOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 559 | 559 | 640 |
| Net profit | −2 | −9 | −7 |
Latest-year revenue ₹640 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- One of the few listed pure-play vaccine makers in India
- Dengue vaccine is a large optionality if Phase 3 succeeds
Risks
- Loss-making since FY23; FY22 profit was a one-off brand sale to Mankind
- Tender-driven revenue and binary clinical outcome
Common questions
What does Panacea Biotec do?
Listed vaccine maker - WHO-prequalified pentavalent (Easyfive-TT) for UNICEF/Gavi, and a dengue vaccine (DengiAll) in Phase 3 with ICMR.
Where does Panacea Biotec sit in the supply chain?
Panacea Biotec (NSE: PANACEABIO) is mapped in 1 supply-chain layer: Biosimilars, vaccines & biologics (Pharmaceuticals).
Who are Panacea Biotec's peers?
In the Biosimilars, vaccines & biologics layer of Pharmaceuticals: Biocon, Serum Institute of India (not NSE-listed), Bharat Biotech (not NSE-listed), Biological E (not NSE-listed), Intas Pharmaceuticals (not NSE-listed), Dr Reddy's Laboratories and 1 more.
What is Panacea Biotec's market cap and valuation?
As of 30 Oct 2026: market cap ₹1,917 Cr, ROCE −2.4%, ROE −2.4%, dividend yield 0%.